Guardant blood test shows promise in predicting immunotherapy response; AstraZeneca's diabetes drug wins EU label expansion
→ The field of liquid biopsy is burgeoning, and each player (there are plenty) is doggedly pursuing consistency and accuracy — false positives induce unnecessary …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
